Status:
UNKNOWN
Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection
Lead Sponsor:
The Second Hospital of Shandong University
Conditions:
Aortic Dissection
Lung Infection
Eligibility:
All Genders
18-90 years
Brief Summary
The individualized drug use research on optimizing piperacillin tazobactam for CRRT of hospital-acquired pulmonary infection after cardiopulmonary bypass is still in the initial stage at home and abro...
Detailed Description
The incidence of acute renal failure after aortic dissection can be as high as 30%. In order to reduce mortality, most patients need continuous renal replacement therapy (CRRT). The concentration of a...
Eligibility Criteria
Inclusion
- Cardiopulmonary bypass during aortic dissection， Lung infection， Continuous renal replacement therapy
Exclusion
- Intracranial infection, Urinary tract infection
Key Trial Info
Start Date :
April 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05349305
Start Date
April 30 2022
End Date
July 30 2024
Last Update
April 27 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.